Latest From Bioprojet
The latest drug development news and highlights from our US FDA Performance Tracker.
FDA’s second half 2019 user fee calendar features almost 30 novel agents, but another record-breaking tally is out of reach.
The French biotech’s lead drug candidate has suffered a clinical-stage setback in narcolepsy, but the Paris-quoted firm is hoping that a Parkinson’s study will give more traction to its pipeline of CNS disease candidates.
- Drug Discovery Tools
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Senior Management
- Jeanne-Marie Lecomte, MD, Chmn. & Managing Dir.
- Contact Info
Phone: (33) 47 03 66 33
30, rue des Francs-Bourgeois
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.